Patents by Inventor Sicai Zhang

Sicai Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL BOTULINUM NEUROTOXIN AND ITS DERIVATIVES
    Publication number: 20220177867
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 9, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • Botulinum neurotoxin and its derivatives
    Patent number: 11286473
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 29, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • Botulinum neurotoxin and its derivatives
    Patent number: 11248218
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 15, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • Engineered botulinum neurotoxins
    Patent number: 11104891
    Abstract: Disclosed herein are modified Clostridial Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial Botulinum serotype B, comprising one or more substitution mutations at positions corresponding 1248 or 1249 in serotype B, strain 1. Specific substitution mutations include I1248F, I1248Y, I1248H, I1248W, V1249W, V1249F, V1249Y, V1249H, I1248W/V1249F, I1248W/V1249Y, I1248W/V1249H, I1248F/V1249Y, I1248F/V1249H, I1248Y/V1249H, I1248F/V1249W, I1248Y/V1249W, I1248H/V1249W, I1248Y/V1249F, I1248H/V1249F, or I1248H/V1249Y. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: August 31, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • NEUROTOXIN-LIKE TOXIN AND USES THEREOF
    Publication number: 20200255481
    Abstract: Provided herein is a novel homolog of Clostridial botulinum neurotoxin (BoNT) identified in the bacterial species Enterococcus faecium (BoNT/EN). BoNT/EN variants and chimeric toxins comprising domains from BoNT/EN and other BoNTs are also provided. Further provided herein are methods of producing BoNT/EN and its use, e.g., in therapeutic applications.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Paul Stenmark, Sicai Zhang, Andrew Doxey
  • A NOVEL BOTULINUM NEUROTOXIN AND ITS DERIVATIVES
    Publication number: 20200224185
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Application
    Filed: July 7, 2017
    Publication date: July 16, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • ENGINEERED BOTULINUM NEUROTOXINS
    Publication number: 20190300869
    Abstract: Disclosed herein are modified Clostridial Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial Botulinum serotype B, comprising one or more substitution mutations at positions corresponding 1248 or 1249 in serotype B, strain 1. Specific substitution mutations include I1248F, I1248Y, I1248H, I1248W, V1249W, V1249F, V1249Y, V1249H, I1248W/V1249F, I1248W/V1249Y, I1248W/V1249H, I1248F/V1249Y, I1248F/V1249H, I1248Y/V1249H, I1248F/V1249W, I1248Y/V1249W, I1248H/V1249W, I1248Y/V1249F, I1248H/V1249F, or I1248H/V1249Y. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 3, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Pau Stenmark
  • A NOVEL BOTULINUM NEUROTOXIN AND ITS DERIVATIVES
    Publication number: 20190136216
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Application
    Filed: July 7, 2017
    Publication date: May 9, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark